GPCR: Structure Therapeutics Inc - American Depositary Shares

GPCR新闻

• 13:20 How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
• 13:15 How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
• 15:24 Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
• 11:31 LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
• 12:17 Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
• 14:11 Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
• 15:08 LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
• 14:30 Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
• 18:31 Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
• 14:37 Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
• 22:45 Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
• 13:23 Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
• 14:00 Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
• 22:00 Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term (SEPN)
• 12:19 NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
• 18:21 Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR)
• 14:19 Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
• 15:46 How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
• 15:09 LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
• 14:26 Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
• 13:42 LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
• 15:10 Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
• 12:20 The BioRevolution Has Accelerated
• 15:43 Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?